Why this page exists
Post-market monitoring plan implementation framework for healthcare deployer teams under Article 72.
Timeline anchor: AI Act in force on August 1, 2024; prohibitions and literacy obligations apply on February 2, 2025; most obligations apply on August 2, 2026; additional rollout continues to August 2, 2027.
Country enforcement context
EU-wide enforcement context for Healthcare: obligations are applied consistently across member states with local supervisory execution.
Industry and risk context
Healthcare evidence baseline: Clinical and operational AI systems that influence care pathways. High-risk scenarios: clinical decision support systems, patient triage automation, care prioritization scoring. Provider risk points: incomplete technical documentation, weak clinical validation controls, insufficient post-market monitoring.
Role obligations
Deployer operational duties: Operate high-risk AI systems with documented human oversight Maintain operational logs and incident workflows Execute FRIA and downstream accountability requirements Buying committee impact typically includes Compliance, Legal, Clinical Ops, IT.
Execution plan
Post-market monitoring plan execution in Healthcare: operational monitoring and incident escalation playbook mapped to Article 72 with release-safe ownership and review cadence.
Commercial fit
Commercial readiness: regulated healthcare teams need operational evidence before August 2, 2026. Annexora converts artifact requirements into delivery plans.
FAQ
Why is post-market monitoring plan critical in healthcare?
Sector-specific operational risk makes evidence consistency and ownership visibility essential for audits.
How should deployer and provider outputs differ?
Deployers optimize operational controls; providers optimize technical documentation and lifecycle assurance.
How fast can this be implemented?
Most teams can stand up a first production-grade version in a four-week pilot with defined owners.